Drugmaker GSK slashes annual profits forecast

Jul 23, 2014

British drugmaker GlaxoSmithKline on Wednesday slashed its 2014 profits forecast as second-quarter earnings sank on the back of weak US trade, adverse currency moves and a Chinese bribery probe.

In a gloomy results statement, GSK said it now expected its earnings per share—a key measure of performance—to be "broadly flat" this year. That compared with the previous forecast for growth of 4.0-8.0 percent.

Net profit, or profit after tax, dived 37 percent to £654 million ($1.11 billion, 827 million euros) in the three months to June 30, down from £1.045 billion in the same period of last year, GSK added.

Total revenues meanwhile tumbled 16 percent to £5.56 billion in the reporting period.

Stripping out the impact of currency fluctuations, revenues fell four percent.

GSK said its performance was hit by "continued increased competition in US respiratory market and generic competition to Lovaza", which is the group's key fish-oil heart drug.

China's corruption probe into its staff continued to weigh on sales, while the group repeated it was fully cooperating with authorities.

"China, acting through various government agencies, continues its investigation into alleged crimes and violations of law by GSK's China operations," GSK said in Wednesday's statement.

"The group takes these allegations seriously and is continuing to cooperate fully with the Chinese authorities in this investigation."

GSK last year admitted senior employees appeared to have breached Chinese law, after Beijing authorities alleged staff had bribed government officials, pharmaceutical industry groups, hospitals and doctors to promote sales.

In May, Britain's Serious Fraud Office launched a criminal investigation into the group's commercial practices.

GSK's share price fell 3.50 percent to 1,500.5 pence, making it the biggest loser in London's benchmark FTSE 100 index, which was up 0.15 percent to 6,805.32 points in afternoon trade.

Explore further: Embattled GlaxoSmithKline hit with another fraud probe

Related Stories

Probe-hit GlaxoSmithKline announces profits slump

Apr 30, 2014

GlaxoSmithKline, the British drugs giant facing a series of probes into alleged staff corruption, announced sliding profits on Wednesday, one week after unveiling a group makeover.

China shuts travel agency in GSK bribery case

Jul 19, 2013

China has shut down a travel agency which served as a conduit for bribes allegedly given by staff of British drug firm GlaxoSmithKline (GSK), the government and state media said.

Drugmaker GSK posts slumping Q1 profits

Apr 24, 2013

British drugs firm GlaxoSmithKline on Wednesday said its first-quarter net profit tumbled by almost a third, with the group hit by falling sales and a poor economic climate.

Recommended for you

Do government technology investments pay off?

Mar 30, 2015

Studies confirm that IT investments in companies improve productivity and efficiency. University of Michigan professor M.S. Krishnan wondered if the same was true for government.

Study finds assisted housing works, but it could be improved

Mar 30, 2015

Two researchers from the University of Kansas Department of Urban Planning have just completed a study on the locations of assisted housing units and assisted households across the nation. It examines one of the key issues ...

Economist probes the high cost of health care

Mar 27, 2015

When Zack Cooper arrived at Yale as assistant professor of public health and economics, he gained access to a first-of-its-kind dataset. Working with the non-profit Health Care Cost Institute, Cooper and ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.